- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
CROI 2025 Insights: Evolving HIV Treatment Landscape and Practice-Changing Developments
A panelist discusses how HIV treatment has evolved with tremendous improvements in efficacy, tolerability, and convenience, with exciting developments at the Conference on Retroviruses and Opportunistic Infections 2025, including new long-acting therapies for treatment and prevention that could last up to 2 years.
EP: 1.HIV Viral Suppression: Clinical Significance and Impact on Patient Outcomes
EP: 2.Changing Patient Demographics in HIV and Impacts of Polypharmacy on Treatment
EP: 3.Phase 3 HIV Treatment Switch Studies: Key Findings From Recent Clinical Trials
EP: 4.HIV Therapy Without Integrase Inhibitor: Practical Advantages and Targeted Patient Populations
EP: 5.Long-Acting HIV Therapies: Real-World Data and Clinical Application
EP: 6.CD4 T-cell and Lymphocyte Monitoring: Clinical Significance in HIV Treatment
EP: 7.CROI 2025 Insights: Evolving HIV Treatment Landscape and Practice-Changing Developments
Future Directions in HIV Treatment
Key Themes:
- Treatment Evolution: Continuous improvement in HIV medications regarding efficacy, tolerability, and convenience
- Long-Acting Formulations: Development of oral, subcutaneous, intramuscular, and intravenous options
- Combination Products: Future devices potentially combining HIV treatment/prevention with contraception or sexually transmitted infection prevention
- HIV Prevention: New preventive therapies potentially effective for 1 to 2 years
Notable Insights from Dr Sharon Walmsley:
- Long-acting therapies help “demedicalize” HIV by reducing medication frequency.
- New challenges in adherence emerge with transition from daily to weekly or monthly dosing schedules.
- HIV treatment advances have informed approaches to other infectious diseases, including COVID-19 and Mpox.
- Despite prevention advances, questions remain about whether to continue vaccine development efforts given limited success to date.
FDA Approves Mepolizumab as First Once-Monthly Biologic for COPD With Eosinophilic Phenotype
May 22nd 2025FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.
Read More
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD
May 17th 2025Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.
Read More
